Arthritis & rheumatology (Hoboken, N.J.)
Interleukin-18 levels are associated with disease course in patients with Still's disease treated with IL-1 inhibitors.
Matteo Trevisan, Manuela Pardeo, Ivan Caiello, Claudia Bracaglia, Arianna de Matteis, Valentina Matteo, Elena Loricchio, Fabrizio De Benedetti, Giusi Prencipe
Published: 202510.1002/art.70024
Abstract
OBJECTIVE: To evaluate the prognostic utility of circulating Interleukin-18 (IL-18) levels in predicting disease activity, macrophage activation syndrome (MAS), and disease course in Still's disease (SD) patients receiving first-line IL-1 inhibitors…
Preview only. Read the full abstract at the source